Altre lingue I-Mab Deutsche Boerse AG

Azioni

0VY

US44975P1030

Tempo reale stimato Tradegate Altri mercati azionari 12:16:17 05/07/2024			Variaz. 5gg	Var. 1 gen.
1,43 ^EUR	+1,42%		-9,62%	-14,55%

06/06	I-Mab nomina Phillip Dennis come Chief Medical Officer	CI
05/06	I-Mab collabora con Bristol-Myers per valutare Givastomig nello studio di combinazione per i tumori gastrici ed esofagei	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06
I-Mab Appoints Phillip Dennis as Chief Medical Officer	06/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23/05
I-Mab to Participate at the Jefferies Global Healthcare Conference	22/05
I-MAB Filed 2023 Annual Report on Form 20-F	30/04
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.	30/04
Verastem Names John Hayslip as Chief Medical Officer	18/04
I-Mab Announces Chief Medical Officer Changes	15/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04
I-Mab Completes Business Divestiture in China	02/04
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04
I-Mab Announces Executive Resignation	01/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue I-Mab Deutsche Boerse AG

Azioni

0VY

US44975P1030

Altre lingue

Filtri